From my post on page 1:”but anybody with symptoms should be able to get it! Not like in NY.”
I don’t understand why this topic has become about a doc named Zelenco!
Anybody who wants to take HCQ – should be able to!
It’s also very puzzleling why Frum Doctors are taking Cuomo’s stand on HCQ.
We as Frum people will do almost anything to save even one life!
From Contagion Live:
“The initial results from a placebo-controlled trial of hydroxychloroquine for COVID-19 indicate that patients hospitalized with mild illness recovered more quickly with addition of the drug than with placebo at the start of a standard treatment. The results also suggest that hydroxychloroquine might convey some protection against the illness worsening.
Zhan Zhang, MD, of Renmin Hospital of Wuhan University, Wuhan, China, and colleagues reported results from 62 patients randomized to receive either placebo or hydroxychloroquine 200mg twice daily for 5 days on admission in addition to standard treatment consisting of oxygen therapy, and unspecified regimens that could include antiviral and antibacterial agents, and immunoglobulin with or without corticosteroids.
“The data in this study revealed that after 5 days of hydroxychloroquine treatment, the symptoms of patients with COVID-19 were significantly relieved, manifesting as shorten(ing) in the recovery time for cough and fever,” Zhang and colleagues reported.
“At the same time, a larger proportion of patients with pulmonary inflammat(ion) has been partially absorbed in the hydroxychloroquine treatment group, indicating the immune modulation and anti-inflammatory properties of hydroxychloroquine in non-malarial diseases,” the researchers indicated.
The measure of time to clinical recovery was defined as return of normal body temperature and cough relief, maintained for 72 hours. A chest CT, obtained before starting the experimental regimen and 1 day after, on day 6 of hospitalization, was characterized as either exacerbated, unchanged, or improved—with 50% or more reduction in opacification classified as significantly improved.
In comparison to the 31 patients on placebo, the 31 receiving the hydroxychloroquine adjunct to standard treatment were reported to have significantly shorter average time to recover normal body temperature (2.2 vs 3.2 days, P = .0008) and time to cessation of cough (2.0 vs 3.1 days, P = .0016). A larger proportion of patients on hydroxychloroquine than placebo also demonstrated an improved chest CT (80.6% vs 54.8%), with 61.3% of the treatment group having significant improvement. In addition, the 4 patients in the trial who deteriorated from mild to severe acuity were all in the placebo group.
“Despite our small number of cases, the potential of hydroxychloroquine in the treatment of COVID-19 has been partially confirmed,” Zhang and colleagues concluded.
“However, large-scale clinical and basic research is still needed to clarify its specific mechanism and to continuously optimize the treatment plan,” they added”
This data is even better than Gilead’s data on their drug Respervir.